Leading Edge Medicine
As the pediatric academic center in mid-Missouri, our physicians are involved in research on the forefront of pediatric oncology. We are an active and accredited member of the Children's Oncology Group with more than 100 available protocols to provide state-of-the-art care of children, adolescents, and young adults with oncologic diagnoses. Our team has also helped collaborate on some of the most important pediatric oncology advances during the past ten years, including:
- Decreased overall childhood cancer mortality by 25%.
- Improved the survival rate of acute lymphoblastic leukemia from 70% to 80%.
- Improved the survival rate of acute non-lymphoblastic leukemia from 35% to 50%.
- Improved the survival rate of the most common form of non-Hodgkins lymphoma from 70% to 90%.
- Improved the survival rate of widespread childhood neuroblastoma from 10% to 45%.
- Reduced by 50% or more the need for radiation therapy for the following groups of patients, thereby reducing risks of long-term effects of radiotherapy:
- acute lymphoblastic leukemia
- infants under 3 years of age with brain tumors
- adolescent girls with Hodgkins disease.
- Established the efficacy of 8 new anti-cancer agents and combinations of such agents for the first time in pediatric cancers.
- Shortened the treatment time for the most common form of non-Hodgkins lymphoma, Hodgkin's disease, and all forms of childhood acute non-lymphoblastic leukemia by 30%-50%.
- Successfully evaluated several agents that reduce the side effects of pediatric cancer treatment.
- Published recommendations for long-term follow-up care for all cancers of children and adolescents.
- Established the first broad effort to develop and evaluate treatments for cancers common to adolescents and young adults, and demonstrated the superiority of pediatric treatment protocols over adult treatment protocols for several cancers of young adults.
We are the home of Missouri's Hemoglobinopathy Center, a state recognized resource providing comprehensive services for individuals and families with sickle cell disease.
We house the University of Missouri's Hemophilia Treatment Center, a part of the federally funded, national HTC network.
Our pediatric hematology clinic is a part of a nationwide CDC-sponsored program called the Universal Data & Serum Specimen Collection on Patients with Hemophilia and Other Bleeding Disorders.
We recently received a National Sickle Cell Registry site designation through a program sponsored by Novartis.
We participate in FDA-recommended Lysosomal Storage Disorders Registries, sponsored by several pharmaceutical companies.
International Association of Sickle Cell Nurses and Physicians Assistants
National Hemophilia Foundation
National Hemophilia Treatment Centers
St. Baldrick's Foundation